Anti-angiogenic therapies in prostate cancer

被引：7

作者：

Maria Martinez-Jabaloyas, Jose ^{[1
,2
]}

Antonio March-Villalba, Jose ^{[1
,2
]}

Mercedes Navarro-Garcia, Maria ^{[1
]}

Dasi, Francisco ^{[1
,3
]}

机构：

[1] Univ Valencia, Inst Invest INCLIVA, Fdn Invest, Hosp Clin, E-46010 Valencia, Spain

[2] Univ Valencia, Hosp Clin, Urol Unit, E-46010 Valencia, Spain

[3] Univ Valencia, Sch Med, Dept Physiol, E-46010 Valencia, Spain

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2013年 / 13卷 / 01期

关键词：

angiogenesis; anti-angiogenic therapies; prostate cancer; review; CHALLENGES;

D O I：

10.1517/14712598.2013.733366

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Prostate cancer (PCa) is the second most common type of cancer among men in Western societies. Once in the castrate-resistant metastatic setting therapeutic options are limited. The importance of angiogenesis in the progression of PCa has been widely reported providing a rationale to test anti-angiogenic compounds for PCa treatment in clinical trials (CTs). However, in spite of the promising results shown in preclinical models and some anti-tumor activity observed in CTs, to date, no angiogenic inhibitor has been approved for use in PCa. This editorial outlines the latest clinical evidence regarding anti-angiogenic therapies in PCa treatment.

引用

页码：1 / 5

页数：5

共 15 条

[1] Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises [J].

Aragon-Ching, Jeanny B. ;

Madan, Ravi A. ;

Dahut, William L. .

JOURNAL OF ONCOLOGY, 2010, 2010

[2] Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients [J].

Attard, Gerhardt ;

de Bono, Johann S. .

CLINICAL CANCER RESEARCH, 2011, 17 (12) :3867-3875

[3] RETRACTED: Horizon scanning for novel therapeutics for the treatment of prostate cancer (Retracted article. See vol. 21, pg. 1591, 2012) [J].

Bianchini, Diletta ;

Zivi, Andrea ;

Sandhu, Shahneen ;

de Bono, Johann S. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (12) :1487-1502

[4] Targeting the tumour vasculature: insights from physiological angiogenesis [J].

Chung, Alicia S. ;

Lee, John ;

Ferrara, Napoleone .

NATURE REVIEWS CANCER, 2010, 10 (07) :505-514

[5] Angiogenesis as a therapeutic target [J].

Ferrara, N ;

Kerbel, RS .

NATURE, 2005, 438 (7070) :967-974

[6] From the discovery of Vascular Endothelial Growth Factor to the introduction of Avastin in clinical trials - an interview with Napoleone Ferrara [J].

Ribatti, Domenico .

INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY, 2011, 55 (4-5) :383-388

[7]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

[8] Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].

Hanahan, D ;

Folkman, J .

CELL, 1996, 86 (03) :353-364

[9] Angiogenesis inhibitors in the treatment of prostate cancer [J].

Hwang, Clara ;

Heath, Elisabeth I. .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3

[10] Current status of anti-angiogenesis therapy for prostate cancer [J].

Jimenez, Juan Antonio ;

Kao, Chinghai ;

Raikwar, Sudhanshu ;

Gardner, Thomas A. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (03) :260-268

← 1 2 →